R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents

  R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents

Business Wire

TOKYO -- February 11, 2013

R-Tech Ueno (JASDAQ: 4573):

Sucampo Pharmaceuticals, Inc. ("Sucampo") announced that it, together with
R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited
("Takeda") and certain affiliates of Takeda, has filed a patent infringement
lawsuit against Anchen Pharmaceuticals, Inc. ("Anchen"), which had filed
Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) to market a generic version of AMITIZA^® (lubiprostone)
oral capsules, and certain affiliates of Anchen. (For more details, please
refer to Sucampo's release dated February 8, 2013)

As a result of Sucampo's filing of the said lawsuit, final FDA approval of
Anchen's ANDA will be stayed up to 30 months from January 2, 2013.

The said filing will have no impact on the forecast of business results for
the fiscal year ending March 2013.

About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the
purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a
medical doctor, the company is developing new drugs on the theme
"Physician-Oriented New Drug Innovation", targeting ophthalmologic and
dermatologic diseases that previously had no effective therapeutic agent.
We aim at becoming a "global pharmaceutical company specializing in specific
fields (ophthalmology and dermatology) and developing and selling
pharmaceutical products through the eyes of doctors." We are promoting the
development of new drugs for unmet medical needs for which the government
provides recommendations and assistance, orphan drugs and the drugs in the
field of anti-aging (lifestyle drugs).

About Lubiprostone

Lubiprostone (trade named Amitiza^®) is a local activator of type-2 chloride
channels in cells lining the small intestine. Lubiprostone increases fluid
secretion into the intestinal tract. This increased fluid level softens the
stool, facilitating intestinal motility and bowel movements. Sucampo
management believes the type 2 chloride channels also play an important role
in the restoration of tight junction complexes and in the recovery of barrier
function in the body.

Amitiza^® is a registered trademark of Sucampo Pharmaceuticals, Inc.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, is
focused on the discovery, development and commercialization of proprietary
drugs based on prostones. The therapeutic potential of prostones, which occur
naturally in the human body as a result of enzymatic, 15-PGDH, transformation
of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D.,
Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno
founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding
Chief Executive Officer and currently Advisor, International Business
Development and a member of the Board of Directors.
For more information about Sucampo Pharmaceuticals, please visit


R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Business Management Department
Press spacebar to pause and continue. Press esc to stop.